Pacira Biosciences vs Travere Therapeutics
Pacira Biosciences is the larger business, with $726m of revenue in fiscal 2025 against $491m for Travere Therapeutics (1.5 times as much). Travere Therapeutics grew faster (110.5% against 3.6%). Pacira Biosciences kept more of each dollar of sales as profit: a net margin of 1.0% against -5.2%.
| Latest fiscal year | Pacira BiosciencesPCRX, 2025 | Travere TherapeuticsTVTX, 2025 |
|---|---|---|
| Revenue | $726m | $491m |
| Revenue growth | 3.6% | 110.5% |
| Net income | $7.0m | −$25.5m |
| Operating margin | 2.6% | — |
| Net margin | 1.0% | -5.2% |
| Return on equity | 1.0% | -29.4% |
| Free cash flow | $137m | $37.8m |
| Cash | $159m | $93.0m |
| Total debt | $372m | $312m |
| Debt to equity | 53.7% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $148m | — |
| Employees | 829 | 497 |
| Market value | $1.45bn | $4.63bn |
| Price vs our value range | Below our value range | — |
| Moat score | 55 (Moderate) | 36 (Weak) |
| Insider trades, 12 months | 0 buys, 17 sales | 0 buys, 119 sales |